# MEDINNO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medinno

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.medinno.kr
- Total disclosed funding: $20M
- Latest round: Series B (Nov 1, 2020)
- Investors on record: 1

## About

Based in Seoul, South Korea, and founded by Kyungmin Joo in 2018, MEDINNO Inc. operates as a biotechnology company specializing in the development of stem cell treatments. In October 2023, the firm raised KRW 11 billion in pre-series C funding led by investor BNH Investment, with participation from other investors CJ Investment, CKD Venture Capital, Mint Venture Partners, and T Investment. The firm as of October 2023, has a production facility in Seoul, and an R&D center in Gyeonggi-do, South Korea. In August 2026, MEDINNO Inc. raised an undisclosed amount of venture funding from Korea Tech Incubator for Startup, being selected for Accelerator Investment-Driven Tech Incubator Program (Scale-up TIPS).

The biopharmaceutical company specializes in the development of cell therapeutics, with an emphasis on Mesenchymal Stem Cells (MSCs), for brain diseases. These stem cells are derived from the umbilical cords of healthy newborns, offering a promising avenue for the treatment of brain diseases. MEDINNO’s flagship product is HIEstem, which is created through Thrombin pre-conditioning, a global patented technology. HIEstem showcases significant neuroprotective effects, including the inhibition of gliosis and inflammation, reducing brain damage, and promoting functional recovery. This product is primarily aimed at treating conditions like Hypoxic Ischemic Encephalopathy (HIE) and Intraventricular Hemorrhage (IVH). Additionally, as of October 2023, the firm is working on the development of Adult Human Neural Stem Cell therapeutics for treating spinal cord injury and strokes, and gene therapies using stem cells for treating Multiple Sclerosis and Brain Tumor.

The company plans to utilize the October 2023 funding to conduct clinical trials of its stem cell treatment candidate in China.

## Funding rounds

- Series B, Nov 1, 2020, $11M — Partners Investment
- Series A, Aug 1, 2019, $6.6M — Partners Investment
- Seed, Jul 1, 2018, $1.8M — Partners Investment

## Investors

- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Seed, Series A, Series B